Formulation Development
Naobios & Sumagen Sign Exclusive Partnership to Develop HIV Vaccine
Naobios will manage process development and initiate launch of cGMP manufacturing for Phase 2 clinical trials….
New Drug Delivery System Developed by Hebrew University Researchers Simultaneously Delivers Diverse Therapeutic Agents in a Single Carrier
A new drug delivery system that overcomes previous limitations in delivering diverse therapeutic compounds in a single carrier has been developed by Hebrew University of…
Neurona Therapeutics Presents Positive Clinical Update From Cell Therapy Trial in Adults With Drug-Resistant Focal Epilepsy
Neurona Therapeutics presented updated preliminary data from its ongoing open-label Phase 1/2 clinical trial of NRTX-1001 in adults with drug-resistant, unilateral mesial temporal lobe epilepsy…
AviadoBio Announces First Patient Treated in Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia With GRN Mutations
AviadoBio recently announced the first patient has been treated in the Phase 1/2 ASPIRE-FTD trial evaluating AviadoBio’s investigational gene therapy, AVB-101, in people with frontotemporal…
NovelMed Receives FDA Orphan Drug Designation for Treating Paroxysmal Nocturnal Hemoglobinuria; Seeks Partnership
NovelMed recently announced the US FDA has awarded Orphan Drug Designation (ODD) to NM5072, an Alternative Pathway (AP) blocker anti-Properdin antibody, for the treatment….
Asahi Kasei Bioprocess & Axolabs Announce Strategic Partnership to Accelerate Oligonucleotide Therapeutics Development
Asahi Kasei Bioprocess (AKB), part of the Asahi Kasei Group, and Axolabs have recently announced a strategic partnership in the burgeoning field of oligonucleotide….
Indaptus Therapeutics Presents Positive Mechanism of Action Data
Indaptus Therapeutics, Inc, recently unveiled its poster at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) in San Diego on April…
Exeliom Biosciences Announces Three Phase 2 Clinical Trials in Immuno-oncology With Lead Candidate Combined With Immune Checkpoint Inhibitors
Exeliom Biosciences recently announced the launch of three Phase 2 clinical studies of its lead candidate EXL01 combined with immune checkpoint inhibitors to target multiple…
Athira Pharma Announces Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma, Inc. recently announced the publication of preclinical data supporting the therapeutic potential of fosgonimeton in Alzheimer’s disease. The original research article, Fosgonimeton Attenuates…
Arvinas Enters Transaction With Novartis, Including Global License Agreement for the Development & Commercialization of Androgen Receptor Protein Degrader
Partnership expected to accelerate and broaden the development of ARV-766 as a potential first-in-class treatment option for patients with prostate cancer….
Century Therapeutics Strengthens Position in Autoimmune Disease With Strategic Pipeline Expansion Supported by $60-Million Private Placement & Acquisition of Clade Therapeutics
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated profile….
MoonLake Immunotherapeutics Signs 3-Year Technology Partnership With Komodo Health
MoonLake Immunotherapeutics and Komodo Health recently announced a new technology partnership to help improve treatment for people living with inflammatory skin and joint diseases. The…
AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock
AdrenoMed AG recently announced the US FDA granted Fast Track designation to its lead product candidate enibarcimab, a first-in-class non-neutralizing monoclonal antibody, for the treatment…
Silo Pharma Set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
Silo Pharma, Inc. recently announced it has exercised its option to license Alzheimer’s disease (AD) therapeutic SPC-14 from Columbia University, pursuant to a sponsored research and option agreement….
Palisade Bio Presents Development Overview for Moderate-to-Severe Ulcerative Colitis Treatment
Palisade Bio, Inc. recently announced it presented at IBD Innovate: Product Development for Crohn’s & Colitis held April 9-10, 2024, in Cambridge, MA. As part…
IO Biotech Presents New Data Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine
IO Biotech recently shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the 2004 American Association for Cancer Research (AACR)…
NeuroSense Collaborates With Lonza to Identify Exosome-Based Biomarkers to Advance Neurodegenerative Disease Treatments & Diagnostics
Lonza and NeuroSense Therapeutics Ltd. recently announced a collaboration to evaluate biological changes occurring in people with neurodegenerative diseases, including ALS. This agreement provides NeuroSense…
Essential Pharma Acquires Renaissance Pharma With its Clinical-Stage Immunotherapy
Essential Pharma recently announced it has completed the acquisition of the entire issued share capital of Renaissance Pharma Ltd. Renaissance Pharma is a clinical-stage pharmaceutical…
4BIO Capital Portfolio Company Ascend Acquires Florida-Based GMP Manufacturing Capacity
Long-Term Partnership Agreed with Beacon Therapeutics for Clinical and Commercial AAV Production….
INmune Bio Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer
INmune Bio, Inc. recently presented data on the use of INB03, a dominant-negative tumor necrosis factor (TNF) inhibitor of soluble TNF (sTNF) in the treatment…
